Xbrane Biopharma AB (publ) (XBRANE.ST)
SEK 0.2
(-2.42%)
SEK 0.2
(-2.42%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 166.07 Million SEK | 206.61% |
| 2022 | -155.77 Million SEK | 37.89% |
| 2021 | -250.79 Million SEK | -5.88% |
| 2020 | -236.87 Million SEK | -53.06% |
| 2019 | -154.76 Million SEK | -201.96% |
| 2018 | -51.25 Million SEK | -655.47% |
| 2017 | -6.78 Million SEK | 74.92% |
| 2016 | -27.05 Million SEK | -2065.85% |
| 2015 | 1.37 Million SEK | 122.19% |
| 2014 | -6.2 Million SEK | 30.14% |
| 2013 | -8.87 Million SEK | -2331.36% |
| 2012 | -365.09 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 93.58 Million SEK | 45.27% |
| 2024 Q2 | 96.21 Million SEK | 346.76% |
| 2024 Q1 | -38.98 Million SEK | -123.48% |
| 2023 Q4 | 166.07 Million SEK | 124.07% |
| 2023 Q1 | -78.4 Million SEK | 49.67% |
| 2023 FY | 166.07 Million SEK | 206.61% |
| 2023 Q3 | 74.11 Million SEK | 205.44% |
| 2023 Q2 | -70.29 Million SEK | 10.34% |
| 2022 FY | -155.77 Million SEK | 37.89% |
| 2022 Q3 | -124.8 Million SEK | 39.85% |
| 2022 Q2 | -207.48 Million SEK | 19.89% |
| 2022 Q1 | -259.01 Million SEK | -3.27% |
| 2022 Q4 | -155.77 Million SEK | -24.81% |
| 2021 Q1 | -191.45 Million SEK | 19.18% |
| 2021 FY | -250.79 Million SEK | -5.88% |
| 2021 Q4 | -250.79 Million SEK | 25.52% |
| 2021 Q3 | -336.71 Million SEK | -303.86% |
| 2021 Q2 | -83.37 Million SEK | 56.45% |
| 2020 Q1 | -75.76 Million SEK | 51.04% |
| 2020 Q4 | -236.87 Million SEK | -103.01% |
| 2020 Q3 | -116.68 Million SEK | 48.06% |
| 2020 FY | -236.87 Million SEK | -53.06% |
| 2020 Q2 | -224.64 Million SEK | -196.5% |
| 2019 Q2 | -165.28 Million SEK | -3272.36% |
| 2019 Q1 | 5.21 Million SEK | 110.17% |
| 2019 FY | -154.76 Million SEK | -201.96% |
| 2019 Q4 | -154.76 Million SEK | -1.98% |
| 2019 Q3 | -151.76 Million SEK | 8.18% |
| 2018 Q1 | 2.1 Million SEK | 130.97% |
| 2018 FY | -51.25 Million SEK | -655.47% |
| 2018 Q4 | -51.25 Million SEK | -443.14% |
| 2018 Q3 | -9.43 Million SEK | -156.68% |
| 2018 Q2 | 16.64 Million SEK | 692.34% |
| 2017 Q1 | -17.1 Million SEK | 36.78% |
| 2017 Q2 | -27.94 Million SEK | -63.42% |
| 2017 Q3 | -23.32 Million SEK | 16.53% |
| 2017 Q4 | -6.78 Million SEK | 70.92% |
| 2017 FY | -6.78 Million SEK | 74.92% |
| 2016 Q2 | -56.69 Million SEK | 17.37% |
| 2016 Q3 | -43.92 Million SEK | 22.53% |
| 2016 Q4 | -27.05 Million SEK | 38.41% |
| 2016 FY | -27.05 Million SEK | -2065.85% |
| 2016 Q1 | -68.6 Million SEK | -5085.74% |
| 2015 Q1 | 6.2 Million SEK | 200.0% |
| 2015 Q3 | -2.81 Million SEK | 0.0% |
| 2015 Q4 | 1.37 Million SEK | 148.89% |
| 2015 FY | 1.37 Million SEK | 122.19% |
| 2014 FY | -6.2 Million SEK | 30.14% |
| 2014 Q4 | -6.2 Million SEK | 0.0% |
| 2013 FY | -8.87 Million SEK | -2331.36% |
| 2012 FY | -365.09 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alzinova AB (publ) | -21.22 Million SEK | 882.423% |
| Amniotics AB (publ) | -5.63 Million SEK | 3048.81% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | 7785.192% |
| BioArctic AB (publ) | -606.58 Million SEK | 127.379% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | -2975.5% |
| Saniona AB (publ) | 40.44 Million SEK | -310.604% |
| Simris Alg AB (publ) | 85.07 Million SEK | -95.212% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 149.78% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | 18093.174% |
| NextCell Pharma AB | -46.79 Million SEK | 454.937% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 665.215% |
| AcouSort AB (publ) | -23.98 Million SEK | 792.391% |
| Active Biotech AB (publ) | -33.2 Million SEK | 600.232% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 432.015% |
| Camurus AB (publ) | -1.16 Billion SEK | 114.251% |
| Cantargia AB (publ) | -139.74 Million SEK | 218.841% |
| Genovis AB (publ.) | -43.94 Million SEK | 477.955% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 298.322% |
| Mendus AB (publ) | -96.29 Million SEK | 272.469% |
| Kancera AB (publ) | -45.69 Million SEK | 463.471% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 302.035% |
| LIDDS AB (publ) | -13.51 Million SEK | 1329.107% |
| Lipum AB (publ) | -8.46 Million SEK | 2061.926% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 620.177% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | -212.04% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 971.338% |
| OncoZenge AB (publ) | -12.62 Million SEK | 1415.253% |
| Xintela AB (publ) | -7.8 Million SEK | 2226.738% |
| Ziccum AB (publ) | -2.13 Million SEK | 7871.502% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 220.217% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 228.25% |
| CombiGene AB (publ) | -101.44 Million SEK | 263.719% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 302.321% |
| Intervacc AB (publ) | -88.16 Million SEK | 288.381% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 432.593% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | -709.737% |
| Corline Biomedical AB | -17.01 Million SEK | 1076.234% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 298.317% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 521.708% |
| Aptahem AB (publ) | 2.9 Million SEK | -5609.778% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 150.47% |
| Fluicell AB (publ) | -2.76 Million SEK | 6110.749% |
| Biovica International AB (publ) | -58.73 Million SEK | 382.747% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 467.289% |
| Abliva AB (publ) | -57.24 Million SEK | 390.142% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 185.299% |
| 2cureX AB (publ) | -13.4 Million SEK | 1339.103% |
| I-Tech AB | -83.26 Million SEK | 299.463% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | -23.287% |
| Cyxone AB (publ) | -16.67 Million SEK | 1096.263% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 397.171% |
| Biosergen AB | -1.88 Million SEK | 8919.809% |
| Nanologica AB (publ) | -9.38 Million SEK | 1869.035% |
| SynAct Pharma AB | -61.75 Million SEK | 368.916% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 875.517% |
| BioInvent International AB (publ) | -236.3 Million SEK | 170.281% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 1355.384% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 348.172% |
| Pila Pharma AB (publ) | -5.18 Million SEK | 3305.55% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 898.716% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | 5688.055% |